IL6 and COVID-19: Mixed survival benefit has been reported with tocilizumab (IL‐6 inhibitor) in patients with severe COVID‐19 [8, 9], suggesting that selective JAK inhibition may be more effective than blocking individual cytokines for treating COVID‐19–associated cytokine storm [3].